Vertex advancing CFTR corrector VX-445 to Phase III

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported data from 65 cystic fibrosis patients with one copy of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation and one minimal function mutation in Part D of

Read the full 348 word article

User Sign In